Pharmaceutical giant Pfizer has decided to scrap development of a drug designed to fight lung cancer, it was recently announced. The drug, tentatively known only as PF-3512676, was shown in trials to be no more effective when combined with chemotherapy than chemo alone, and the drug manufacturers behind it reasoned that it wasn't worth investing any additional revenue into. Nonetheless, a significant amount has already been poured in to the drug, so it comes a big hit for Pfizer and partnering company Coley.Pfizer, in the meantime, continues working on several other cancer drugs, including ones for breast and colorectal cancers.
